Trump Fast-Tracks Psychedelic Treatments, Boosting Biotech Stocks
President Donald Trump has fast-tracked the approval process for psychedelic treatments for mental illnesses, directing the FDA to reduce review times from six to ten months to one or two months. This policy change is expected to benefit several biotech firms, with Compass Pathways and AtaiBeckley seeing significant stock price increases.
Topics: biotech stocks FDA mental health psychedelic treatments regulatory approval stock market reaction